The effect between metabolic syndrome and life expectancy after cancer diagnosis: Catalan cohort study
Abstract This study examines remaining life expectancy (RLE) after a cancer diagnosis, focusing on age, sex, cancer type, and metabolic syndrome (MS) components, using data from the SIDIAP database in Catalonia (2006–2017). RLE was analyzed for 13 cancer types, stratified by sex and MS components. T...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Public Health |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12889-025-21437-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594321725980672 |
|---|---|
| author | Tomàs López-Jiménez Oleguer Plana-Ripoll Talita Duarte-Salles Anna Palomar-Cros Diana Puente |
| author_facet | Tomàs López-Jiménez Oleguer Plana-Ripoll Talita Duarte-Salles Anna Palomar-Cros Diana Puente |
| author_sort | Tomàs López-Jiménez |
| collection | DOAJ |
| description | Abstract This study examines remaining life expectancy (RLE) after a cancer diagnosis, focusing on age, sex, cancer type, and metabolic syndrome (MS) components, using data from the SIDIAP database in Catalonia (2006–2017). RLE was analyzed for 13 cancer types, stratified by sex and MS components. The cohort study includes 183,364 individuals followed from diagnosis until death, transfer, or study end (December 2017). RLE at age 68 (median diagnosis age) was calculated based on MS components (0, 1, 2, and ≥ 3). Men aged 68 with 0 MS components had an RLE of 13.2 years, compared to 8.9 years for those with ≥ 3 MS. Women had an RLE of 15.9 years with 0 MS components versus 11.4 years with ≥ 3 MS. RLE varied by cancer type, with the highest RLE in men seen in prostate cancer and in women in non-Hodgkin lymphoma. The lowest RLE for both sexes was in pancreatic cancer. The largest differences between 0 and ≥ 3 MS components were observed in non-Hodgkin lymphoma and the smallest in pancreatic cancer. Increased MS components were associated with reduced RLE in at least 8 cancer types for men and 9 for women. Prevention strategies targeting MS components could increase RLE in cancer patients. |
| format | Article |
| id | doaj-art-1d070e670d3f429485baa89d98157e53 |
| institution | Kabale University |
| issn | 1471-2458 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Public Health |
| spelling | doaj-art-1d070e670d3f429485baa89d98157e532025-01-19T12:41:37ZengBMCBMC Public Health1471-24582025-01-0125111210.1186/s12889-025-21437-9The effect between metabolic syndrome and life expectancy after cancer diagnosis: Catalan cohort studyTomàs López-Jiménez0Oleguer Plana-Ripoll1Talita Duarte-Salles2Anna Palomar-Cros3Diana Puente4Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)Department of Clinical Epidemiology, Aarhus University and Aarhus University HospitalFundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)Abstract This study examines remaining life expectancy (RLE) after a cancer diagnosis, focusing on age, sex, cancer type, and metabolic syndrome (MS) components, using data from the SIDIAP database in Catalonia (2006–2017). RLE was analyzed for 13 cancer types, stratified by sex and MS components. The cohort study includes 183,364 individuals followed from diagnosis until death, transfer, or study end (December 2017). RLE at age 68 (median diagnosis age) was calculated based on MS components (0, 1, 2, and ≥ 3). Men aged 68 with 0 MS components had an RLE of 13.2 years, compared to 8.9 years for those with ≥ 3 MS. Women had an RLE of 15.9 years with 0 MS components versus 11.4 years with ≥ 3 MS. RLE varied by cancer type, with the highest RLE in men seen in prostate cancer and in women in non-Hodgkin lymphoma. The lowest RLE for both sexes was in pancreatic cancer. The largest differences between 0 and ≥ 3 MS components were observed in non-Hodgkin lymphoma and the smallest in pancreatic cancer. Increased MS components were associated with reduced RLE in at least 8 cancer types for men and 9 for women. Prevention strategies targeting MS components could increase RLE in cancer patients.https://doi.org/10.1186/s12889-025-21437-9Metabolic syndromeCancerRemaining life expectancySurvival |
| spellingShingle | Tomàs López-Jiménez Oleguer Plana-Ripoll Talita Duarte-Salles Anna Palomar-Cros Diana Puente The effect between metabolic syndrome and life expectancy after cancer diagnosis: Catalan cohort study BMC Public Health Metabolic syndrome Cancer Remaining life expectancy Survival |
| title | The effect between metabolic syndrome and life expectancy after cancer diagnosis: Catalan cohort study |
| title_full | The effect between metabolic syndrome and life expectancy after cancer diagnosis: Catalan cohort study |
| title_fullStr | The effect between metabolic syndrome and life expectancy after cancer diagnosis: Catalan cohort study |
| title_full_unstemmed | The effect between metabolic syndrome and life expectancy after cancer diagnosis: Catalan cohort study |
| title_short | The effect between metabolic syndrome and life expectancy after cancer diagnosis: Catalan cohort study |
| title_sort | effect between metabolic syndrome and life expectancy after cancer diagnosis catalan cohort study |
| topic | Metabolic syndrome Cancer Remaining life expectancy Survival |
| url | https://doi.org/10.1186/s12889-025-21437-9 |
| work_keys_str_mv | AT tomaslopezjimenez theeffectbetweenmetabolicsyndromeandlifeexpectancyaftercancerdiagnosiscatalancohortstudy AT oleguerplanaripoll theeffectbetweenmetabolicsyndromeandlifeexpectancyaftercancerdiagnosiscatalancohortstudy AT talitaduartesalles theeffectbetweenmetabolicsyndromeandlifeexpectancyaftercancerdiagnosiscatalancohortstudy AT annapalomarcros theeffectbetweenmetabolicsyndromeandlifeexpectancyaftercancerdiagnosiscatalancohortstudy AT dianapuente theeffectbetweenmetabolicsyndromeandlifeexpectancyaftercancerdiagnosiscatalancohortstudy AT tomaslopezjimenez effectbetweenmetabolicsyndromeandlifeexpectancyaftercancerdiagnosiscatalancohortstudy AT oleguerplanaripoll effectbetweenmetabolicsyndromeandlifeexpectancyaftercancerdiagnosiscatalancohortstudy AT talitaduartesalles effectbetweenmetabolicsyndromeandlifeexpectancyaftercancerdiagnosiscatalancohortstudy AT annapalomarcros effectbetweenmetabolicsyndromeandlifeexpectancyaftercancerdiagnosiscatalancohortstudy AT dianapuente effectbetweenmetabolicsyndromeandlifeexpectancyaftercancerdiagnosiscatalancohortstudy |